ABN.AS: $40.75 ▲ 0.30 (0.74%)DSFIR.AS: $99.66 ▼ -0.99 (-0.98%)GMAB.CO: $2,487.00 ▲ 42.00 (1.72%)REP.MC: $29.21 ▼ -0.31 (-1.05%)SOON.SW: $267.80 ▲ 3.20 (1.21%)CRWD: $263.34 ▼ -11.70 (-4.25%)HPE: $70.10 ▼ -3.36 (-4.57%)AMD: $590.61 ▼ -17.49 (-2.88%)DELL: $574.44 ▼ -11.62 (-1.98%)PANW: $399.92 ▼ -18.86 (-4.50%)MRNA: $214.33 ▼ -10.67 (-4.74%)AAPL: $339.63 ▲ 2.99 (0.89%)AMZN: $259.90 ▼ -2.53 (-0.96%)MSFT: $540.03 ▲ 4.96 (0.93%)NVDA: $226.58 ▼ -2.70 (-1.18%)CIEN: $403.01 ▼ -46.76 (-10.40%)DDOG: $288.28 ▼ -4.98 (-1.70%)SNPS: $503.23 ▼ -6.77 (-1.33%)CAP.PA: $115.35 ▲ 0.30 (0.26%)TSCO.L: $511.00 ▲ 7.20 (1.43%)WKL.AS: $77.16 ▲ 2.16 (2.88%)

Company Details

Bone Biologics Corporation

BBLGW - NASDAQ

Identifiants & Marche

Ticker BBLGW
ISIN US0980701546
CIK 0001419554
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Medical - Devices

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.